CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
about
Profile of palbociclib in the treatment of metastatic breast cancerThe progress of early growth response factor 1 and leukemiaGenetic and Epigenetic Mechanisms That Maintain Hematopoietic Stem Cell FunctionCDK6 levels regulate quiescence exit in human hematopoietic stem cells.Targeting cell cycle regulators in hematologic malignancies.Does CDKN2A loss predict palbociclib benefit?CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1FOXM1 is a therapeutic target for high-risk multiple myeloma.Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases.Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.miR-139-5p controls translation in myeloid leukemia through EIF4G2.HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of action, Clinical Activity, and Safety Profiles.Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).CCND1-CDK4-mediated cell cycle progression provides a competitive advantage for human hematopoietic stem cells in vivo.Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype.The IRX1/HOXA connection: insights into a novel t(4;11)- specific cancer mechanismAn essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemiaCdk6 contributes to cytoskeletal stability in erythroid cells.CDK6 is a regulator of stem cells "Egr" to wake upH19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma.CBX3 promotes colon cancer cell proliferation by CDK6 kinase-independent function during cell cycle.MicroRNA-124 Targets Tip110 Expression and Regulates Hematopoiesis.Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.Targeting CDK6 and BCL2 exploits the "MYB addiction" of Ph+ acute lymphoblastic leukemia.Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer.JAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/β-catenin/CCND1 signaling.MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.Med23 serves as a gatekeeper of the myeloid potential of hematopoietic stem cellsOmega 3 polyunsaturated fatty acids inhibit cell proliferation by regulating cell cycle in fad3b transgenic mouse embryonic stem cells
P2860
Q26747737-486527C2-9A17-4379-A09A-953AA627E3A7Q26748151-8CF9771C-4ECC-4C86-81AF-FE7FB5660069Q26770001-C5C85327-4472-4DA5-9BCD-6E610C7F3BCFQ35175470-BEE40AC8-471E-4F22-B612-65F0B34E49C9Q35334436-4E5D148D-D254-40A3-BAE0-762BDDC2EC1EQ36394640-49FF795E-F626-4BA7-B029-D1DF3E0CCCF6Q36463738-0E1576C7-C60D-4E20-8CCC-0A89852E9C45Q36783627-0E9D1574-496B-442B-B54F-38E871E0A330Q36827351-D0AFC150-2A15-48C5-940D-F0E677AECC52Q37037268-C4C17757-FDEB-426F-8065-6817501D76D3Q38616175-E18571C8-21D4-4445-AEF4-CA008FE5A8A1Q38675849-F08FAD99-0AFA-48D1-B7B3-FA13A5C1A8E2Q38854034-A0D959A9-3EDC-4C29-8C1C-3FE6B9717642Q38866877-DB6BA2E7-2D97-4414-A175-36D17EA0CD8CQ38949247-F0F80545-0E41-4C33-B891-75E07E5A4296Q40762555-6A3E4BF7-B1C7-449B-8506-68EFCBB45A42Q41363689-A395323D-8E5F-4E20-8BAF-DF544E01296CQ41610527-AF5311E9-4E57-49C7-BEB4-EACED86DED1DQ41819724-7453F849-CC29-4241-8B2B-02AD7C2EADF0Q41949980-0B26A04A-1660-47A3-90BB-73270FB2BB77Q42154652-4CC732C4-B3D9-4F18-93BC-922B43091795Q42239876-8C678457-2CEB-40A4-A6ED-26FA93F00715Q42292339-308D20BB-558E-4C7C-B340-FD04E4C118A4Q42726342-A76EDFE7-D894-4A62-BD80-D7C907C3CA2AQ47130109-ADB8AE19-7DC8-4D2D-BBCE-8828F8E89B10Q47443248-4645588B-62E9-4CBF-A481-07898150F8B8Q48571436-85829526-B0C5-40A4-9342-2F8CDC8A2743Q50333196-9C568AC1-536F-42AD-8360-AB060A3110D4Q52628082-9BC00176-4D0C-45D7-B869-8023CD24D7E9Q53275543-7391E3C2-73FB-4D3A-BD30-B99E12149AA9Q58740792-A16E738D-8AD7-4176-ABC6-2D201FEE2F17Q58757922-DCD9E71E-FBA0-4FF7-87F9-FFC1500537D0
P2860
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
description
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artikull shkencor
@sq
artículu científicu espublizáu en 2015
@ast
im Januar 2015 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2015
@uk
مقالة علمية (نشرت عام 2015)
@ar
name
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
@ast
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
@en
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
@nl
type
label
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
@ast
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
@en
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
@nl
prefLabel
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
@ast
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
@en
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
@nl
P2093
P2860
P50
P3181
P1433
P1476
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
@en
P2093
Anca-Sarmiza Tigan
Christine Schneckenleithner
Florian Bellutti
Karoline Kollmann
Michaela Prchal-Murphy
Ruth Scheicher
Veronika Sexl
P2860
P304
P3181
P356
10.1182/BLOOD-2014-06-584417
P407
P50
P577
2015-01-01T00:00:00Z